Hatfield Laura A, Kramer Daniel B, Volya Rita, Reynolds Matthew R, Normand Sharon-Lise T
Harvard Medical School, Boston, MA
Harvard Medical School, Boston, MA Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, MA.
J Am Heart Assoc. 2016 Jul 28;5(8):e003532. doi: 10.1161/JAHA.116.003532.
Cardiac implantable electric devices are commonly used to treat heart failure. Little is known about temporal and geographic variation in use of cardiac resynchronization therapy (CRT) devices in usual care settings.
We identified new CRT with pacemaker (CRT-P) or defibrillator generators (CRT-D) implanted between 2008 and 2013 in the United States from a commercial claims database. For each implant, we characterized prior medication use, comorbidities, and geography. Among 17 780 patients with CRT devices (median age 69, 31% women), CRT-Ps were a small and increasing share of CRT devices, growing from 12% to 20% in this study period. Compared to CRT-D recipients, CRT-P recipients were older (median age 76 versus 67), and more likely to be female (40% versus 30%). Pre-implant use of β-blockers and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers was low in both CRT-D (46%) and CRT-P (31%) patients. The fraction of CRT-P devices among all new implants varied widely across states. Compared to the increasing national trend, the share of CRT-P implants was relatively increasing in Kansas and relatively decreasing in Minnesota and Oregon.
In this large, contemporary heart failure population, CRT-D use dwarfed CRT-P, though the latter nearly doubled over 6 years. Practice patterns vary substantially across states and over time. Medical therapy appears suboptimal in real-world practice.
心脏植入式电子设备常用于治疗心力衰竭。在常规护理环境中,对于心脏再同步治疗(CRT)设备使用的时间和地理差异知之甚少。
我们从一个商业索赔数据库中识别出2008年至2013年在美国植入起搏器(CRT-P)或除颤器发生器(CRT-D)的新型CRT。对于每一次植入,我们对先前的药物使用、合并症和地理位置进行了描述。在17780例植入CRT设备的患者中(中位年龄69岁,31%为女性),CRT-P在CRT设备中所占比例较小且呈上升趋势,在本研究期间从12%增长到20%。与接受CRT-D的患者相比,接受CRT-P的患者年龄更大(中位年龄76岁对67岁),且女性比例更高(40%对30%)。在CRT-D患者(46%)和CRT-P患者(31%)中,植入前β受体阻滞剂和血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂的使用率都很低。CRT-P设备在所有新植入设备中所占比例在各州差异很大。与全国上升趋势相比,堪萨斯州CRT-P植入的比例相对上升,而明尼苏达州和俄勒冈州则相对下降。
在这个大型的当代心力衰竭人群中,CRT-D的使用量远远超过CRT-P,尽管后者在6年中几乎翻了一番。不同州和不同时间的实践模式差异很大。在实际临床实践中,药物治疗似乎并不理想。